Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Eradication of established tumors by CD8+ T cell adoptive immunotherapy.

Immunity - 1 Aug 2000

Hanson H L, Donermeyer D L, Ikeda H, White J M, Shankaran V, Old L J, Shiku H, Schreiber R D, Allen P M

Abstract excerpt

We generated the DUC18 T cell receptor transgenic mouse expressing an H-2Kd -restricted transgenic T cell receptor specific for the syngeneic CMS5 fibrosarcoma rejection antigen mutated ERK2(136-144). DUC18 mice were capable of specifically eliminating lethal CMS5 tumor challenges, and transfer of DUC18 splenocytes to naive nontransgenic recipients conferred protection from subsequent and established CMS5 tumor...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antigens, Neoplasm
Share to CD8-Positive T-Lymphocytes

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Cytotoxicity, Immunologic

Share to Fibrosarcoma

Share to Immunotherapy, Adoptive

Share to Mice, Transgenic

Share to Receptors, Antigen, T-Cell

Source

Identifiers

PMID: 10981969
DOI: 10.1016/s1074-7613(00)00026-1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Eradication of established tumors by CD8+ T cell adoptive immunotherapy.PMID 10981969Read ↗

Successful elimination of large established tumors and avoidance of antigen-loss variants by aggressive adoptive T cell immunotherapy.Semantic proximity Read ↗

Exploiting the curative potential of adoptive T‐cell therapy for cancerSemantic proximity Read ↗

DSG2-Directed CAR-T Cells Safely and Universally Eliminate Solid TumorsSemantic proximity Read ↗

Selective cytotoxic T-lymphocyte targeting of tumor immune escape variants.Semantic proximity Read ↗

Adoptive cellular immunotherapy of cancer in mice using allogeneic T-cells.Semantic proximity Read ↗

Reversion analysis reveals the in vivo immunogenicity of a poorly MHC I-binding cancer neoepitope.Semantic proximity Read ↗

Cutting edge: permissive MHC class II allele changes the pattern of antitumor immune response resulting in failure of tumor rejection.Semantic proximity Read ↗

Long-lasting complete regression of established mouse tumors by counteracting Th2 inflammation.Semantic proximity Read ↗

Limited tumor infiltration by activated T effector cells restricts the therapeutic activity of regulatory T cell depletion against established melanoma.Semantic proximity Read ↗

A2A adenosine receptor protects tumors from antitumor T cells.Semantic proximity Read ↗

Tumor-specific CD4(+) suppressor T-cell clone capable of inhibiting rejection of syngeneic sarcoma in A/J mice.Semantic proximity Read ↗

Reconstitution models to evaluate natural killer T cell function in tumor control.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.